Meeting
2017 Gastrointestinal Cancers Symposium
Outcomes in the second line treatment of metastatic colorectal cancer (mCRC): Findings from 6,462 patients (pts) in the ARCAD database.
Authors
Alexis Diane Leal
Mayo Clinic, Rochester, MN
Alexis Diane Leal , Fang-Shu Ou , Aimery De Gramont , Levi Pederson , Alberto F. Sobrero , Marc Peeters , Dirk Arnold , Henry C. Pitot , Mace L. Rothenberg , Bruce J. Giantonio , Eric Van Cutsem , Daniel J. Sargent , Axel Grothey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 757)
DOI
10.1200/JCO.2017.35.4_suppl.757
Abstract #
757
Poster Bd #
M1
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
MOUNTAINEER: open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
First Author: John H. Strickler
Poster
2014 ASCO Annual Meeting
Second-line therapies in patients with KRAS wild-type metastatic colorectal cancer (mCRC) after first-line therapy with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK0306 (FIRE 3) trial.
First Author: Dominik Paul Modest
Poster
2011 ASCO Annual Meeting
Phase II study of panitumumab with irinotecan for patients with KRAS wild-type metastatic colorectal cancer (MCRC) refractory to standard chemotherapy: A GERCOR study.
First Author: B. Chibaudel
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer (mCRC) refractory to anti-EGFR antibodies.
First Author: Atsushi Ishiguro